We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+10.41%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$571M
AUM Growth
-$28.1M
Cap. Flow
-$28.6M
Cap. Flow %
-5.01%
Top 10 Hldgs %
76.16%
Holding
50
New
6
Increased
12
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
IMNM icon
Immunome
IMNM
+$9.7M
2
ARVN icon
Arvinas
ARVN
+$8.99M
3
EPIX
ESSA Pharma
EPIX
+$7.04M
4
CRGX
CARGO Therapeutics
CRGX
+$3.78M
5
DNA icon
Ginkgo Bioworks
DNA
+$3.26M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$23M
2
APLT
Applied Therapeutics
APLT
+$11.2M
3
OCUL icon
Ocular Therapeutix
OCUL
+$6.66M
4
CYTK icon
Cytokinetics
CYTK
+$3.98M
5
CPRX
Catalyst Pharmaceutical
CPRX
+$2.24M

Sector Composition

Rank Sector Weight
1 Healthcare 98.12%
2 Miscellaneous 1.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HROW icon
1
Harrow
HROW
$1.44B
$134M 23.43%
3,990,000
– –
TGTX icon
2
TG Therapeutics
TGTX
$8.53B
$68M 11.9%
2,260,000
-20,000
-0.9% -$574K
CDXS icon
3
Codexis
CDXS
$182M
$42.2M 7.38%
8,840,000
+70,000
+0.8% +$288K
ETON icon
4
Eton Pharmaceutcials
ETON
$1.79B
$38M 6.65%
2,852,070
+72,070
+3% +$731K
OCUL icon
5
Ocular Therapeutix
OCUL
$2.38B
$37.1M 6.49%
4,342,500
-682,500
-14% -$6.66M
ARVN icon
6
Arvinas
ARVN
$604M
$33.6M 5.89%
1,625,000
+370,000
+29% +$8.99M
RYTM icon
7
Rhythm Pharmaceuticals
RYTM
$7.75B
$28M 4.9%
500,000
– –
IMNM icon
8
Immunome
IMNM
$3.28B
$21.7M 3.79%
2,040,000
+802,500
+65% +$9.7M
LQDA icon
9
Liquidia Corp
LQDA
$6.26B
$20M 3.49%
1,698,142
– –
EWTX icon
10
Edgewise Therapeutics
EWTX
$4.8B
$12.8M 2.24%
480,000
-42,500
-8% -$1.35M
DNA icon
11
Ginkgo Bioworks
DNA
$489M
$11.8M 2.06%
1,200,000
+379,798
+46% +$3.26M
CRGX
12
DELISTED
CARGO Therapeutics
CRGX
$10.8M 1.89%
750,000
+208,563
+39% +$3.78M
TARA icon
13
Protara Therapeutics
TARA
$236M
$9.64M 1.69%
1,825,000
+143,846
+9% +$465K
TRVI icon
14
Trevi Therapeutics
TRVI
$2.56B
$9.55M 1.67%
2,317,500
-250,490
-10% -$802K
JSPR icon
15
Jasper Therapeutics
JSPR
$23.3M
$8.55M 1.5%
400,000
+46,500
+13% +$968K
NAMS icon
16
NewAmsterdam Pharma
NAMS
$3.2B
$8.35M 1.46%
325,000
-10,000
-3% -$212K
SLRN
17
DELISTED
ACELYRIN
SLRN
$7.17M 1.26%
2,235,000
+341,340
+18% +$1.65M
NRIX icon
18
Nurix Therapeutics
NRIX
$2.79B
$7.13M 1.25%
378,500
-41,500
-10% -$951K
XOMA
19
DELISTED
Xoma
XOMA
$6.57M 1.15%
250,000
– –
PCVX icon
20
Vaxcyte
PCVX
$9.1B
$6.14M 1.07%
75,000
-10,000
-12% -$993K
ZNTL icon
21
Zentalis Pharmaceuticals
ZNTL
$367M
$5.36M 0.94%
1,767,500
+800,500
+83% +$2.62M
BDSX icon
22
Biodesix
BDSX
$300M
$5.3M 0.93%
173,250
-17,500
-9% -$515K
NUVL
23
DELISTED
Nuvalent
NUVL
$4.58M 0.8%
58,500
-5,500
-9% -$514K
GOSS icon
24
Gossamer Bio
GOSS
$83.2M
$4.06M 0.71%
4,490,000
+824,990
+23% +$707K
PTGX icon
25
Protagonist Therapeutics
PTGX
$9.67B
$4.05M 0.71%
105,000
– –
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2024 Portfolio in Review

As of Q4 2024, Opaleye Management held 50 positions worth $571M, down 4.7% from $600M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Opaleye Management withdrew a net $28.6M in Q4 2024, closing 11 positions and reducing 12 holdings. Its most notable exit was Keros Therapeutics, an estimated $23M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in ESSA Pharma worth $3.96M.

  • Opaleye Management's largest Q4 2024 buy was ESSA Pharma: 2,209,998 shares worth $3.96M.
  • Opaleye Management added most to Immunome in Q4 2024, an estimated $9.7M increase.
  • Opaleye Management's biggest Q4 2024 reduction was Ocular Therapeutix, cutting an estimated $6.66M.
  • Opaleye Management fully exited Keros Therapeutics in Q4 2024, selling an estimated $23M.
  • Opaleye Management's ten largest holdings make up 76% of its $571M portfolio in Q4 2024.
  • Opaleye Management opened 6 new positions and closed 11 in Q4 2024.
  • Opaleye Management's portfolio value fell 4.7% quarter-over-quarter to $571M.

Based on Opaleye Management's 13F filing for Q4 2024, filed 14 Feb 2025.